Macroalgae are increasingly viewed as a source of secondary metabolites with great potential for the development of new drugs. In this development, in vitro studies are only the first step in a long process, while in vivo studies and clinical trials are the most revealing stages of the true potential and limitations that a given metabolite may have as a new drug. This literature review aims to give a critical overview of the secondary metabolites that reveal the most interesting results in these two steps. Phlorotannins show great pharmaceutical potential in in vivo models and, among the several examples, the anti-dyslipidemia activity of dieckol must be highlighted because it was more effective than lovastatin in an in vivo model. The IRLIIVLMPILMA tridecapeptide that exhibits an in vivo level of activity similar to the hypotensive clinical drug captopril should still be stressed, as well as griffithsin which showed such stunning results over a variety of animal models and which will probably move onto clinical trials soon. Regarding clinical trials, studies with pure algal metabolites are scarce, limited to those carried out with kahalalide F and fucoxanthin. The majority of clinical trials currently aim to ascertain the effect of algae consumption, as extracts or fractions, on obesity and diabetes.Studies focusing on the preparation of macroalgae extracts and their chemical characterization revealed a large range of seaweed compounds with very interesting biological activities including antitumor, anti-inflammatory, antimicrobial, antidiabetic, antivirus, antihypertensive, fat-lowering, and neuroprotective activities [12][13][14][15].The large volume of studies proving the seaweed compound activities in in vitro systems [16][17][18][19] hints the need for further advancements in the knowledge about macroalgae compound efficiency in living systems (in vivo) and their use in the development of pharmaceuticals. In vitro studies are very relevant and yield very important information, but they only represent the first step of a long process, and the results obtained rarely reveal anything about the effects of a compound in vivo, because the responses observed in vitro can be magnified, diminished, or totally different in a more complex and integrated system. In fact, in vivo studies and clinical trials are those which contribute most to truly understanding the real potential of compounds as future pharmaceuticals.In this regard, the present work intends to present insight into the results obtained in the last few years regarding secondary metabolites, such as phlorotannins, halogenated compounds, fucoxanthin, and fucosterol isolated from macroalgae, involved in in vivo studies and clinical trials, identifying the research opportunities and knowledge gaps, to valorize these compounds and their natural resources. The intention is not to present an exhaustive survey of all published works, but rather a selection of authors based on the following criteria: in-depth studies involving pure compounds most characteristic f...
Seaweed beach-casts are a seasonal phenomenon that regularly deposits tons of algae biomass on beaches, which are usually disposed of in landfills. The present work aimed to contribute to the valorization of this biomass by studying bioactivities that reveal its potential in the pharmaceutical and/or cosmeceutical industries. Methanol and ethanol extracts and fractions from 15 beach-casts biomass were tested for a range of bioactivities. Eight of the most active samples exhibit IC50 values between 11.38 µg/mL and 19.28 µg/mL and selectivity indexes higher than 3.8, against NCI-H1299 (lung cancer) and T47D (breast cancer). Concerning antiaging potential, all the extracts tested presented UV protection, with SPF values above 30, like the standard sunscreen. Regarding aging-related enzymes, 24 samples were tyrosinase inhibitors exhibiting IC50 values from 9.01 µg/mL to 200.09 µg/mL. Eight extracts inhibited collagenase (IC50 < 248.76 µg/mL), two of them more actively than positive control EDTA (IC50 = 59.26 µg/mL). In addition to UV protection, the cumulative effect of antityrosinase and anticollagenase activities shown by the samples suggest that they may play a significant role in preventing skin photoaging. The results obtained demonstrate the high potential of beach-cast seaweed biomass as sources of cosmetic bioproducts with antiaging effects, and of selective cytotoxic metabolites.
Three macroalgae collected at Madeira Island were included in this study to determine their potential for drug, nutraceutical, food, or supplement application. Fatty acid content was higher in Zonaria tournefortii (12.32 mg g −1 dw) with 16.58% of PUFAs, eicosapentaenoic acid (C20:5ω3), and arachidonic acid (20:4ω6) having concentrations of 2.59 and 1.17%, respectively. The anti-thrombogenic and anti-atherogenicity potential was higher for Z. tournefortii due to relevant fatty acids in the biochemical composition this macroalgae. Lipid classes were assessed in the lipid extract and neutral lipids (NL) were in higher yield in Asparagopsis taxiformis (51.16%) and lower in Z. tournefortii (26.96%). The glycolipids (GL) were between 36.03 and 16.11% in Z. tournefortii and Ulva lactuca. Phospholipids (PL) fraction varied from 35.91 and 31.60% in A. taxiformis and Z. tournefortii. TLC screening identified that U. lactuca contains phytol and cholesterol in its NL, digalactosyldiacylglycerol in its GL, and cardiolipin and L-α-phosphatidylcholine in its PL. Zonaria tournefortii contains phytol and cholesterol in its NL classes, and the PL classes contain L-α-phosphatidylethanolamine and 1-(3-sn-phosphatidyl)-rac-glycerol. The macroalgae A. taxiformis revealed cholesterol in its NL fraction and the same phospholipids as Z. tournefortii in its PL fraction. ATR-FTIR analysis enabled a "fingerprint" spectra and important sulfation absorption bands were identified, revealing the functional polysaccharides within these macroalgae. Anti-cholinesterasic activity was assessed in A. taxiformis, with a low IC 50 for AChE (8.92 ± 0.43 μg mL −1) and BuChE (13.96 ± 0.32 μg mL −1), demonstrating dual inhibitory activity, justifying the interest to identify the active principle which may be the scaffold of a novel drug.
Chalcones and flavanones are isomeric structures and also classes of natural products, belonging to the flavonoid family. Moreover, their wide range of biological activities makes them key scaffolds for the synthesis of new and more efficient drugs. In this work, the synthesis of hydroxy and/or methoxychalcones was studied using less common bases, such as sodium hydride (NaH) and lithium bis(trimethylsilyl)amide (LiHMDS), in the aldol condensation. The results show that the use of NaH was more effective for the synthesis of 2 -hydroxychalcone derivatives, while LiHMDS led to the synthesis of polyhydroxylated chalcones in a one-pot process. During this study, it was also possible to establish the conditions that favor their isomerization into flavanones, allowing at the same time the synthesis of hydroxy and/or methoxyflavanones. The chalcones and flavanones obtained were evaluated to disclose their antioxidant, anticholinesterasic, antibacterial and antitumor activities. 2 ,4 ,4-Trihydroxychalcone was the most active compound in terms of antioxidant, anti-butyrylcholinesterase (IC 50 26.55 ± 0.55 µg/mL, similar to control drug donepezil, IC 50 28.94 ± 1.76 µg/mL) and antimicrobial activity. 4 ,7-Dihydroxyflavanone presented dual inhibition, that is, the ability to inhibit both cholinesterases. 4 -Hydroxy-5,7-dimethoxyflavanone and 2 -hydroxy-4-methoxychalcone were the compounds with the best antitumor activity. The substitution pattern and the biological assay results allowed the establishment of some structure/activity relationships.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.